Premium
Expression of NUANCE, a potential novel oncogene, is inhibited by nonsteroidal anti‐inflammatory drugs (NSAIDs) in human colorectal cancer cells
Author(s) -
Liggett Jason Lee,
Choi Chang Kyoung,
Donnell Robert L,
English Anthony E,
Kihm Kenneth David,
Baek Seung Joon
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.1_supplement.1031.1
Subject(s) - oncogene , cancer research , colorectal cancer , biology , cancer , medicine , cell cycle
NSAIDs are well known for treating inflammatory disease and have been reported to have an anti‐tumorigenic affect. Our lab has previously shown that NSAIDs also induce other anti‐tumorigenic genes including NSAID activated gene (NAG‐1). This makes NSAIDs a prime candidate for further study. HCT‐116 cells treated with sulindac sulfide (SS) showed dramatic morphological changes under differential interference contrast microscopy as well as weakened cellular adhesion as measured by micro‐impedance. Microarray analysis was performed using HCT‐116 cells treated with SS, and NUANCE (NUA), a novel connection between the actin skeleton and the nuclear envelope, was selected based on its novelty in relation to cell adhesion and biogenesis. SS diminished NUA mRNA expression by one third and various other NSAIDs also showed inhibition of NUA. Additionally, immunohistochemistry showed higher levels of NUA in tumors of many tissues. Further micro‐impedance experiments on cells with shRNA NUA showed a reduction in cellular adhesion. Thus, our data suggest that NUA may be a potential novel oncogene in human colorectal cancer cells and NSAIDs could decrease its expression. ACS RSG‐06‐124‐01